In this episode, we review ASCVD risk estimation and lipid-lowering therapies. What low-density lipoprotein cholesterol (LDL-C) level should be targeted for patients who have had an ASCVD event versus those who have not, and how do these target LDL-C levels vary based on the presence of risk factors, diabetes status, and estimated 10-year ASCVD risk? What equation recently replaced the pooled cohort equations for estimating 10-year risk of ASCVD, and what new variables are introduced in the updated equation? What does high, moderate, and low intensity statin mean? In which two populations do you bypass the classic ASCVD risk chart for statin initiation and go straight for a high-intensity statin? What events and conditions comprise the definition of secondary prevention patients who are at "very high risk" of additional ASCVD events? How do these differ from the primary prevention risk enhancing factors? Furthermore, how do these differ from the diabetes-specific risk enhancing factors? In what situations is it appropriate to obtain a coronary artery calcium (CAC) score? What are the implications of a CAC score of 0, 1-99, and 100+? What is the definition of statin intolerance? Which statins are hydrophilic and which are lipophilic? Which statins are metabolized by CYP3A and which are metabolized by CYP2C9? What non-statin therapies are available for additional lipid lowering? What is the difference between the Friedewald equation and the Martin-Hopkins equation? How often do you need to be checking a lipid panel? Tune in for answers to these questions.

Difficulty Level: Easy

You are listening to Hu Said: Cardiology Board Review Series (2024-2025 Season)

Please subscribe, rate, and support the channel! Ads help keep materials free for everyone.

More MedEd resources available at ⁠⁠⁠www.rueyhu.com⁠⁠⁠

Updates at Twitter/X: ⁠⁠⁠@Ruey_Hu⁠⁠